7,8-Dichloro-1-oxo-β-carbolines as a Versatile Scaffold for the Development of Potent and Selective Kinase Inhibitors with Unusual Binding Modes

Development of both potent and selective kinase inhibitors is a challenging task in modern drug discovery. The innate promiscuity of kinase inhibitors largely results from ATP-mimetic binding to the kinase hinge region. We present a novel class of substituted 7,8-dichloro-1-oxo-β-carbolines based on the distinct structural features of the alkaloid bauerine C whose kinase inhibitory activity does not rely on canonical ATP-mimetic hinge interactions. Intriguingly, cocrystal structures revealed an unexpected inverted binding mode and the presence of halogen bonds with kinase backbone residues. The compounds exhibit excellent selectivity over a comprehensive panel of human protein kinases while inhibiting selected kinases such as the oncogenic PIM1 at low nanomolar concentrations. Together, our biochemical and structural data suggest that this scaffold may serve as a valuable template for the design and development of specific inhibitors of various kinases including the PIM family of kinases, CLKs, DAPK3 (ZIPK), BMP2K (BIKE), and others.

[1]  O. Franco,et al.  Pim1 kinase synergizes with c-MYC to induce advanced prostate carcinoma , 2010, Oncogene.

[2]  S. Knapp,et al.  Structural analysis identifies imidazo[1,2-b]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity. , 2007, Cancer research.

[3]  K. Tsuneyama,et al.  Proto‐oncogene, Pim‐3 with serine/threonine kinase activity, is aberrantly expressed in human colon cancer cells and can prevent Bad‐mediated apoptosis , 2007, Cancer science.

[4]  Shinji Yamazaki,et al.  Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma , 2007, Molecular Cancer Therapeutics.

[5]  K. Huber,et al.  A Versatile Synthesis of 3-Substituted 4-Cyano-1,2,3,4-tetrahydro-1-oxo-β-carbolines. , 2011 .

[6]  P. Ekman,et al.  Pim‐1 expression in prostatic intraepithelial neoplasia and human prostate cancer , 2004, The Prostate.

[7]  Anastassis Perrakis,et al.  Automated protein model building combined with iterative structure refinement , 1999, Nature Structural Biology.

[8]  Stefan Knapp,et al.  Synthesis, kinase inhibitory potencies, and in vitro antiproliferative evaluation of new Pim kinase inhibitors. , 2009, Journal of medicinal chemistry.

[9]  T. Meyer,et al.  Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. , 1996, Cancer research.

[10]  Z. Otwinowski,et al.  [20] Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[11]  P. Meltzer,et al.  Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival. , 2005, Blood.

[12]  宁北芳,et al.  疟原虫var基因转换速率变化导致抗原变异[英]／Paul H, Robert P, Christodoulou Z, et al//Proc Natl Acad Sci U S A , 2005 .

[13]  Hiroshi Ishikura,et al.  Pim-3, a proto-oncogene with serine/threonine kinase activity, is aberrantly expressed in human pancreatic cancer and phosphorylates bad to block bad-mediated apoptosis in human pancreatic cancer cell lines. , 2006, Cancer research.

[14]  T. Satoh,et al.  [Reduction of organic compounds with sodium borohydride-transition metal salt systems. 3. Preparation of 2-aminomethyl-1,1-diphenyl-1-butene]. , 1970, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.

[15]  H. Bessler,et al.  Increased Expression of the hPim-2 Gene In Human Chronic lymphocytic Leukemia and Non-Hodgkin Lymphoma , 2004, Leukemia & lymphoma.

[16]  T. Hunter,et al.  The Protein Kinase Complement of the Human Genome , 2002, Science.

[17]  Stefan Knapp,et al.  Structure and Substrate Specificity of the Pim-1 Kinase* , 2005, Journal of Biological Chemistry.

[18]  V. Walsh,et al.  The MRC Laboratory of Molecular Biology , 1997, Current Biology.

[19]  Z. Otwinowski,et al.  Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[20]  Stefan Knapp,et al.  PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers , 2010, Haematologica.

[21]  M. Wilmanns,et al.  Molecular Basis of the Death-Associated Protein Kinase–Calcium/Calmodulin Regulator Complex , 2010, Science Signaling.

[22]  Jun Li,et al.  Structural Basis of Constitutive Activity and a Unique Nucleotide Binding Mode of Human Pim-1 Kinase* , 2005, Journal of Biological Chemistry.

[23]  Martin Stahl,et al.  Corrections to A Medicinal Chemist’s Guide to Molecular Interactions , 2010, Journal of Medicinal Chemistry.

[24]  F. Sigaux,et al.  The human protooncogene product p33pim is expressed during fetal hematopoiesis and in diverse leukemias. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Giuseppe Zanotti,et al.  Inspecting the structure-activity relationship of protein kinase CK2 inhibitors derived from tetrabromo-benzimidazole. , 2005, Chemistry & biology.

[26]  S. Knapp,et al.  Structural basis of inhibitor specificity of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM-1) kinase. , 2005, Journal of medicinal chemistry.

[27]  A. Zelenetz,et al.  Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma , 2011, The Journal of experimental medicine.

[28]  Z. Hall.  Cancer , 1906, The Hospital.

[29]  Jaeki Min,et al.  Discovery of cyclin-dependent kinase inhibitor, CR229, using structurebased drug screening. , 2007, Journal of microbiology and biotechnology.

[30]  Kevin Cowtan,et al.  research papers Acta Crystallographica Section D Biological , 2005 .

[31]  M. Kinter,et al.  DAPK-ZIPK-L13a axis constitutes a negative-feedback module regulating inflammatory gene expression. , 2008, Molecular cell.

[32]  Damian Szklarczyk,et al.  Specific CLK Inhibitors from a Novel Chemotype for Regulation of Alternative Splicing , 2011, Chemistry & biology.

[33]  P. Kocieňski,et al.  Protecting groups , 1999 .

[34]  S. Knapp,et al.  Crystal Structure of the PIM2 Kinase in Complex with an Organoruthenium Inhibitor , 2009, PloS one.

[35]  I. W. Cheney,et al.  Identification and structure-activity relationships of substituted pyridones as inhibitors of Pim-1 kinase. , 2007, Bioorganic & medicinal chemistry letters.

[36]  M. Botta,et al.  Synthesis, modeling, and RET protein kinase inhibitory activity of 3- and 4-substituted beta-carbolin-1-ones. , 2008, Journal of medicinal chemistry.

[37]  M. Lilly,et al.  Comparative molecular field analysis of flavonoid inhibitors of the PIM-1 kinase. , 2007, Bioorganic & medicinal chemistry.

[38]  F. Bracher.  Polycyclische aromatische Alkaloide, 10. Mitt.: Annonaceen‐Alkaloide mit antimykotischer Aktivität , 1994 .

[39]  P. Dubey,et al.  Unexpected Regiospecific Reduction of the Double Bond by NaBH4 in 2‐(1‐Methyl/1H‐benzimidazole‐2‐yl)‐3‐aryl‐acrylonitrile , 2007 .

[40]  ヤクルト本社.  Cell Signalling , 1998, The Journal of physiology.

[41]  V. Stoll,et al.  Discovery of 3H-benzo[4,5]thieno[3,2-d]pyrimidin-4-ones as potent, highly selective, and orally bioavailable inhibitors of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM) kinases. , 2009, Journal of medicinal chemistry.

[42]  G. Murshudov,et al.  Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.

[43]  T. Haystead,et al.  ZIP kinase, a key regulator of myosin protein phosphatase 1. , 2005, Cellular signalling.

[44]  C. Homon,et al.  Hit to lead account of the discovery of a new class of inhibitors of Pim kinases and crystallographic studies revealing an unusual kinase binding mode. , 2009, Journal of medicinal chemistry.

[45]  F. Bracher,et al.  Total Syntheses of the Chlorinated β‐Carboline Alkaloids Bauerine A, B, and C , 2007 .

[46]  Jay Painter,et al.  Electronic Reprint Biological Crystallography Optimal Description of a Protein Structure in Terms of Multiple Groups Undergoing Tls Motion Biological Crystallography Optimal Description of a Protein Structure in Terms of Multiple Groups Undergoing Tls Motion , 2005 .

[47]  Randy J Read,et al.  Electronic Reprint Biological Crystallography Likelihood-enhanced Fast Translation Functions Biological Crystallography Likelihood-enhanced Fast Translation Functions , 2022 .

[48]  Y. Ban,et al.  An Efficient Reduction of Nitriles and Amides to the Corresposnding Amines with Tetra-N-butylammonium Borohydride in Dichloromethane , 1980 .

[49]  J. Oyarzábal,et al.  Pim 1 kinase inhibitor ETP-45299 suppresses cellular proliferation and synergizes with PI3K inhibition. , 2011, Cancer letters.

[50]  G. Patterson,et al.  beta-Carbolines from the blue-green alga Dichothrix baueriana. , 1994, Journal of natural products.

[51]  Gouri Nanjangud,et al.  Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas , 2001, Nature.

[52]  A. Kimchi,et al.  DAPk Protein Family and Cancer , 2006, Autophagy.